<DOC>
	<DOCNO>NCT02125604</DOCNO>
	<brief_summary>The primary objective study evaluate effect symptomatic therapy gastrointestinal-related event report participant relapsing-remitting multiple sclerosis initiate therapy BG00012 ( dimethyl fumarate , DMF ) clinical practice set . The secondary objective study study population follow : To evaluate gastrointestinal-related event require symptomatic therapy role therapy time ; To evaluate gastrointestinal-related event lead physician 's decision manage event BG00012 dose modification ; To evaluate gastrointestinal-related event lead BG00012 discontinuation use symptomatic therapy .</brief_summary>
	<brief_title>Gastrointestinal Tolerability Study Of Dimethyl Fumarate ( DMF ) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Have confirm diagnosis relapsingremitting multiple sclerosis ( RRMS ) accord current McDonald Criteria satisfy therapeutic indication describe official local registration Tecfidera ( dimethyl fumarate ) . Naïve dimethyl fumarate ( DMF ) fumaric acid ester . Key Female subject currently pregnant breastfeed consider become pregnant study History significant gastrointestinal disease ( e.g. , irritable bowel disease , peptic ulcer disease , history major gastrointestinal surgery ) , chronic use gastrointestinal related symptomatic therapy determine Investigator ( ≥7 consecutive day gastrointestinal related symptomatic therapy Known active malignancy History anaphylaxis severe allergic reaction know drug hypersensitivity Current use B vitamin supplement In opinion Investigator , blood test value suggestive low lymphocyte count renal hepatic impairment , describe product label precaution use . NOTE : Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Gastrointestinal event</keyword>
</DOC>